Literature DB >> 20811327

RhoC GTPase activation assay.

Michelle Lucey1, Heather Unger, Kenneth L van Golen.   

Abstract

RhoC GTPase has 91% homology to RhoA GTPase. Because of its prevalence in cells, many reagents and techniques for RhoA GTPase have been developed. However, RhoC GTPase is expressed in metastatic cancer cells at relatively low levels. Therefore, few RhoC-specific reagents have been developed. We have adapted a Rho activation assay to detect RhoC GTPase. This technique utilizes a GST-Rho binding domain fusion protein to pull out active RhoC GTPase. In addition, we can harvest total protein at the beginning of the assay to determine levels of total (GTP and GDP bound) RhoC GTPase. This allows for the determination of active versus total RhoC GTPase in the cell. Several commercial versions of this procedure have been developed however, the commercial kits are optimized for RhoA GTPase and typically do not work well for RhoC GTPase. Parts of the assay have been modified as well as development of a RhoC-specific antibody.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811327      PMCID: PMC3156014          DOI: 10.3791/2083

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  9 in total

1.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.

Authors:  Kenneth L van Golen; LiWei Bao; Melinda M DiVito; ZhiFen Wu; George C Prendergast; Sofia D Merajver
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

2.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

Authors:  K L van Golen; Z F Wu; X T Qiao; L W Bao; S D Merajver
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

3.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

Authors:  K L van Golen; Z F Wu; X T Qiao; L Bao; S D Merajver
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

4.  RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility.

Authors:  H Yao; E J Dashner; C M van Golen; K L van Golen
Journal:  Oncogene       Date:  2006-04-13       Impact factor: 9.867

5.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

Authors:  Christopher L Hall; Cara W Dubyk; Tracy A Riesenberger; Daniel Shein; Evan T Keller; Kenneth L van Golen
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

6.  Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.

Authors:  Kenneth L van Golen; Li Wei Bao; Quintin Pan; Fred R Miller; Zhi Fen Wu; Sofia D Merajver
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis.

Authors:  Linda Sequeira; Cara W Dubyk; Tracy A Riesenberger; Carlton R Cooper; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2008-05-07       Impact factor: 5.150

8.  CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.

Authors:  Kenneth L van Golen; Chi Ying; Linda Sequeira; Cara W Dubyk; Tracy Reisenberger; Arul M Chinnaiyan; Kenneth J Pienta; Robert D Loberg
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

9.  Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior.

Authors:  E E Sander; J P ten Klooster; S van Delft; R A van der Kammen; J G Collard
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.